Management of cytotoxic chemotherapy-induced hand-foot syndrome

  • Johannes J.M. Kwakman | j.j.kwakman@amsterdamumc.nl Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Yannick S. Elshot Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Cornelis J.A. Punt Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Miriam Koopman Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Abstract

Improvements in systemic cancer treatments have resulted in more patients surviving for prolonged periods of time on treatment. This has made treatment-related toxicity and quality of life concerns increasingly relevant. Hand-foot syndrome (HFS) is a common skin reaction to systemic therapy that should be anticipated with chemotherapeutic treatments such as pegylated liposomal doxorubicin, docetaxel, and fluoropyrimidines. In this review we discuss current knowledge of the diagnosis, incidence, pathogenesis, and management of hand-foot syndrome (HFS). Although HFS is not life threatening, it can cause significant discomfort and impairment of function, especially in elderly patients, and may seriously impact quality of life. The incidence of HFS is dependent on the chemotherapeutic drug used, the treatment schedule, and the median duration of treatment. Effective measures for prevention and treatment of HFS include systemic and topical treatments, dose reductions, and switching to other drugs in the same class that are associated with lower rates of HFS. These approaches allow patients to continue cancer treatment while reducing negative impacts on quality of life. Awareness and early recognition are important to ensure timely treatment and avoidance of dose reductions or treatment discontinuation. We provide useful recommendations to guide the management of HFS in clinical practice.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-05-13
Info
Issue
Section
Reviews
Keywords:
Hand-foot syndrome, quality of life, fluoropyrimidines, doxorubicin, docetaxel.
Statistics
  • Abstract views: 72

  • PDF: 38
  • HTML: 0
How to Cite
Kwakman, J. J., Elshot, Y. S., Punt, C. J., & Koopman, M. (2020). Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncology Reviews, 14(1). https://doi.org/10.4081/oncol.2020.442